WallStSmart

Enbridge Inc (ENB)vsGilead Sciences Inc (GILD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Enbridge Inc generates 121% more annual revenue ($65.19B vs $29.44B). GILD leads profitability with a 28.9% profit margin vs 11.5%. GILD appears more attractively valued with a PEG of 0.38. GILD earns a higher WallStSmart Score of 72/100 (B).

ENB

Strong Buy

67

out of 100

Grade: B-

Growth: 5.3Profit: 6.5Value: 10.0Quality: 4.5
Piotroski: 3/9Altman Z: 0.61

GILD

Strong Buy

72

out of 100

Grade: B

Growth: 5.3Profit: 9.5Value: 10.0Quality: 5.5
Piotroski: 6/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ENBUndervalued (+53.1%)

Margin of Safety

+53.1%

Fair Value

$109.98

Current Price

$54.48

$55.50 discount

UndervaluedFair: $109.98Overvalued
GILDUndervalued (+53.9%)

Margin of Safety

+53.9%

Fair Value

$299.95

Current Price

$138.26

$161.69 discount

UndervaluedFair: $299.95Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ENB3 strengths · Avg: 9.0/10
Debt/EquityHealth
0.1010/10

Conservative balance sheet, low leverage

Market CapQuality
$116.68B9/10

Large-cap with strong market position

Price/BookValuation
2.9x8/10

Reasonable price relative to book value

GILD6 strengths · Avg: 9.3/10
PEG RatioValuation
0.3810/10

Growing faster than its price suggests

Return on EquityProfitability
40.7%10/10

Every $100 of equity generates 41 in profit

Operating MarginProfitability
37.4%10/10

Strong operational efficiency at 37.4%

Market CapQuality
$171.45B9/10

Large-cap with strong market position

Profit MarginProfitability
28.9%9/10

Keeps 29 of every $100 in revenue as profit

EPS GrowthGrowth
23.4%8/10

Earnings expanding 23.4% YoY

Areas to Watch

ENB4 concerns · Avg: 3.3/10
PEG RatioValuation
1.824/10

Expensive relative to growth rate

EPS GrowthGrowth
2.9%4/10

2.9% earnings growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Altman Z-ScoreHealth
0.612/10

Distress zone — elevated risk

GILD1 concerns · Avg: 4.0/10
Revenue GrowthGrowth
4.7%4/10

4.7% revenue growth

Comparative Analysis Report

WallStSmart Research

Bull Case : ENB

The strongest argument for ENB centers on Debt/Equity, Market Cap, Price/Book.

Bull Case : GILD

The strongest argument for GILD centers on PEG Ratio, Return on Equity, Operating Margin. Profitability is solid with margins at 28.9% and operating margin at 37.4%. PEG of 0.38 suggests the stock is reasonably priced for its growth.

Bear Case : ENB

The primary concerns for ENB are PEG Ratio, EPS Growth, Piotroski F-Score.

Bear Case : GILD

The primary concerns for GILD are Revenue Growth.

Key Dynamics to Monitor

ENB carries more volatility with a beta of 0.86 — expect wider price swings.

ENB is growing revenue faster at 5.9% — sustainability is the question.

GILD generates stronger free cash flow (3.1B), providing more financial flexibility.

Monitor OIL & GAS MIDSTREAM industry trends, competitive dynamics, and regulatory changes.

Bottom Line

GILD scores higher overall (72/100 vs 67/100), backed by strong 28.9% margins. ENB offers better value entry with a 53.1% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Enbridge Inc

ENERGY · OIL & GAS MIDSTREAM · USA

Enbridge Inc. is an energy infrastructure company. The company is headquartered in Calgary, Canada.

Gilead Sciences Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.

Want to dig deeper into these stocks?